Patents by Inventor Loany Calvo Gonzalez

Loany Calvo Gonzalez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for making a homogenous vaccine composition comprising a conjugate of EGF and 64K for the treatment of tumors
    Patent number: 8841251
    Abstract: A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: September 23, 2014
    Assignee: Centro de Immunologia Molecular (CIM)
    Inventors: Gryssell Rodriguez Martinez, Lisel Vina Rodriguez, Loany Calvo Gonzalez, Ariadna Cuevas Fiallo, Ernesto Chico Veliz, Agustin Bienvenido Lage Davila, Tania Crombet Ramos, Arama Albisa Novo, Gisela Maria Gonzalez Marinello
  • Homogeneous vaccine composition comprising a conjugate of EGF and P64K for the treatment of tumors
    Patent number: 8778879
    Abstract: The present invention concerns the biotechnology sector and more specifically human healthcare. In particular, the present invention describes a vaccine composition for therapeutic use thereof on cancer patients. The vaccine composition described in the present invention has as active principle a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and are combining protein P64k. In addition, specific conditions are described for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. In another embodiment, the present invention concerns a method for purification of the chemical conjugate which not only provides greater purity for the therapeutic composition, but surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans.
    Type: Grant
    Filed: June 26, 2008
    Date of Patent: July 15, 2014
    Assignee: Centro de Inmunologia Molecular (CIM)
    Inventors: Gryssell María Rodríguez Martínez, Lisel Viña Rodríguez, Loany Calvo González, Ariadna Cuevas Fiallo, Ernesto Chico Véliz, Agustín Bienvenido Lage Dávila, Tania Crombet Ramos, Airama Albisa Novo, Gisela Maria González Marinello
  • Homogenous Vaccine Composition Comprising a Conjugate of EGF and P64K for the Treatment of Tumors
    Publication number: 20130039940
    Abstract: A vaccine composition for therapeutic use thereof on cancer patients includes a chemical conjugate of human recombining Epidermic Growth Factor (hrEGF) and a combining protein P64k for performing a conjugation reaction which produces said chemical conjugate in a controlled and reproducible manner. The preferred conjugate surprisingly increases the immunogenic activity causing significant increases in the anti-EGF antibody titers in humans, and provides a vaccine preparation with more than one type of effective dose presentation which enables the immunization dose per patient to be increased, but without involving an increase in immunization frequency and/or the number of immunization sites.
    Type: Application
    Filed: January 10, 2012
    Publication date: February 14, 2013
    Inventors: Gryssell Rodriguez Martinez, Lisel Vina Rodriguez, Loany Calvo Gonzalez, Ariadna Cuevas Fiallo, Ernesto Chico Veliz, Agustin Bienvenido Lage Davila, Tania Crombet Ramos, Arama Albisa Novo, Gisela Maria Gonzalez Marinello